As global financial landscapes shift, Noah outlines a new AI-first approach to helping families protect and grow their wealth.
Updated
January 8, 2026 6:31 PM
Noah’s Black Diamond Summit. PHOTO: ARK WEALTH
Noah Holdings, one of Asia’s leading wealth management firms serving global Chinese high-net-worth families, hosted its annual Black Diamond Summit in Macau from December 7–11. The city has become a significant gathering place for Noah’s community, where clients, partners, and experts converge each year to explore how global trends are transforming wealth and family life. This year’s theme, “AI Together, Co-Generating the Future”, set the tone for a conversation about how modern wealth management must adapt in an age defined by artificial intelligence.
More than 3,000 attendees joined discussions that connected technology, global mobility, and long-term family planning. The Summit built on earlier sessions held in Shanghai, creating a continuous dialogue around one central question: how can families prepare for a world that is becoming more digital, more complex and more interconnected?
A major moment came when Noah introduced “Noya”, its new AI Relationship Manager. Noya is now part of the upgraded iARK Hong Kong and Singapore apps. It is built to support licensed human advisors, not replace them. The goal is simple: combine human judgment with AI intelligence to help clients understand their wealth more clearly and manage it across borders. Noya offers real-time insights, deeper personalisation, cleaner access to global financial information, smoother coordination between regions, and end-to-end execution through Noah’s global booking centres.
The Summit’s tone shifted toward long-term thinking when Co-Founder and Chairwoman Norah Wang delivered her keynote, “From Chaos to Clarity: Building a Global Operating System for Wealth Management”. She reflected on twenty years of serving more than 400,000 clients and explained that families today face new pressures. As she put it, “The real pain point for Chinese families today is not investment performance, but navigating the growing complexities of a global lifestyle”. Her message was straightforward: wealth is no longer just about returns. It is about managing uncertainty in a world where technology, geopolitics, and mobility collide.
Wang described how two major shifts have shaped modern wealth—first the Internet Era, which changed how people built wealth, and now what she calls the AI Civilisation Era, which is changing how people must protect it. She outlined the forces that influence today’s decisions: geopolitical shifts, persistent inflation, the rising importance of security and supply-chain technologies, the spread of AI, and the need for stronger family governance across generations. Each of these factors adds complexity, and families need tools that help them see the bigger picture.
To respond to this reality, Noah presented its integrated global wealth infrastructure. It is built on three pillars:
Together, these pillars function as an AI-supported system designed to simplify global complexity and help families preserve long-term stability.
One of the most discussed conversations featured Noah’s CEO, Zander Yin, and Tony Shale, Co-Founder & Chairman of Asian Private Banker China. They spoke about how AI is transforming private banking in Asia. Their view was that wealth management is moving from a product-centred model to one led by insight, trust, and human-tech collaboration. AI may accelerate analysis, but human expertise will continue to guide judgment, relationships, and long-term strategy.
The closing message of the Summit centred on redefining what prosperity means in an AI-driven age. For Noah, wealth is no longer a destination. It is an ongoing journey through a world that is increasingly fast-moving and unpredictable. As Wang noted, “With AI reshaping the very foundations of civilisation, wealth and financial freedom represent not a static endpoint, but a continuous journey. Here, we find our purpose: to help global Chinese investors navigate an increasingly complex world and achieve true prosperity, supported by resilient wealth management infrastructure and deep human expertise”.
The Summit ended on that note—a reminder that the future of wealth is not only about financial assets, but about clarity, confidence and the ability to adapt as the world transforms.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.